File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Loss/down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma
  • Basic View
  • Metadata View
  • XML View
TitleLoss/down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma
 
AuthorsYang, G1 1
He, W1
Cai, M1
Luo, F1
Kung, H1
Guan, X1
Zeng, Y1
Xie, D1
 
KeywordsImmunohistochemistry
Ovarian tumor
Prognosis
TSLC1
 
Issue Date2011
 
PublisherLippincott Williams & Wilkins. The Journal's web site is located at tp://www.ijgc.net/
 
CitationInternational Journal Of Gynecological Cancer, 2011, v. 21 n. 3, p. 486-493 [How to Cite?]
DOI: http://dx.doi.org/10.1097/IGC.0b013e31820fa168
 
AbstractObjectives: The tumor suppressor in lung cancer 1 (TSLC1) has been identified as a putative tumor suppressor gene in non-small cell lung cancer. Although loss of TSLC1 has been observed in a number of human malignancies, the expression levels of TSLC1 gene in ovarian cancer and its clinical or prognostic significance have not been investigated. Methods: Protein expression levels of TSLC1 was explored by semiquantitative immunohistochemical staining on archival formalin-fixed, paraffin-embedded pathological specimen consisting of 30 normal ovaries, 30 ovarian cystadenomas, 40 borderline ovarian tumors, and 160 invasive ovarian carcinomas. The TSLC1 immunohistochemical staining results were then correlated with various clinicopathologic parameters and patient prognosis using various statistical models. Results: Significantly decreased, or complete loss of, protein expression of the TSLC1 gene was observed in 59%ovarian carcinomas, 45% borderline tumors, and 7% cystadenomas, but in none of the normal ovaries (0%). In ovarian carcinomas, decreased TSLC1 expression was significantly correlated with lymph node metastasis (pN, P = 0.001), distant metastasis (pM, P = 0.028), and more advanced International Federation of Gynecology and Obstetrics stages (P = 0.008). By univariate survival analysis on the ovarian carcinoma cohorts, decreased TSLC1 protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P < 0.001). By multivariate analysis, TSLC1 protein expression remained as a significant and independent prognostic factor for the prediction of patient survival (P = 0.003). Conclusions: Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma. Thus, TSLC1 may be used as an independent prognostic molecular marker for patients with ovarian carcinoma. Copyright © 2011 by IGCS and ESGO.
 
ISSN1048-891X
2012 Impact Factor: 1.941
2012 SCImago Journal Rankings: 0.762
 
DOIhttp://dx.doi.org/10.1097/IGC.0b013e31820fa168
 
ISI Accession Number IDWOS:000288743700011
Funding AgencyGrant Number
Nature Science Foundation of China30772334
973 Project of China2010CB912802
2010CB529401
Guangdong Science and Technology Agency2004B35001004
Funding Information:

This study was supported by the grants from the Nature Science Foundation of China (no. 30772334), the 973 Project of China (no. 2010CB912802 and 2010CB529401), and Project of Guangdong Science and Technology Agency (no. 2004B35001004).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorYang, G
 
dc.contributor.authorHe, W
 
dc.contributor.authorCai, M
 
dc.contributor.authorLuo, F
 
dc.contributor.authorKung, H
 
dc.contributor.authorGuan, X
 
dc.contributor.authorZeng, Y
 
dc.contributor.authorXie, D
 
dc.date.accessioned2011-08-26T14:22:13Z
 
dc.date.available2011-08-26T14:22:13Z
 
dc.date.issued2011
 
dc.description.abstractObjectives: The tumor suppressor in lung cancer 1 (TSLC1) has been identified as a putative tumor suppressor gene in non-small cell lung cancer. Although loss of TSLC1 has been observed in a number of human malignancies, the expression levels of TSLC1 gene in ovarian cancer and its clinical or prognostic significance have not been investigated. Methods: Protein expression levels of TSLC1 was explored by semiquantitative immunohistochemical staining on archival formalin-fixed, paraffin-embedded pathological specimen consisting of 30 normal ovaries, 30 ovarian cystadenomas, 40 borderline ovarian tumors, and 160 invasive ovarian carcinomas. The TSLC1 immunohistochemical staining results were then correlated with various clinicopathologic parameters and patient prognosis using various statistical models. Results: Significantly decreased, or complete loss of, protein expression of the TSLC1 gene was observed in 59%ovarian carcinomas, 45% borderline tumors, and 7% cystadenomas, but in none of the normal ovaries (0%). In ovarian carcinomas, decreased TSLC1 expression was significantly correlated with lymph node metastasis (pN, P = 0.001), distant metastasis (pM, P = 0.028), and more advanced International Federation of Gynecology and Obstetrics stages (P = 0.008). By univariate survival analysis on the ovarian carcinoma cohorts, decreased TSLC1 protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P < 0.001). By multivariate analysis, TSLC1 protein expression remained as a significant and independent prognostic factor for the prediction of patient survival (P = 0.003). Conclusions: Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma. Thus, TSLC1 may be used as an independent prognostic molecular marker for patients with ovarian carcinoma. Copyright © 2011 by IGCS and ESGO.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationInternational Journal Of Gynecological Cancer, 2011, v. 21 n. 3, p. 486-493 [How to Cite?]
DOI: http://dx.doi.org/10.1097/IGC.0b013e31820fa168
 
dc.identifier.doihttp://dx.doi.org/10.1097/IGC.0b013e31820fa168
 
dc.identifier.epage493
 
dc.identifier.hkuros190875
 
dc.identifier.isiWOS:000288743700011
Funding AgencyGrant Number
Nature Science Foundation of China30772334
973 Project of China2010CB912802
2010CB529401
Guangdong Science and Technology Agency2004B35001004
Funding Information:

This study was supported by the grants from the Nature Science Foundation of China (no. 30772334), the 973 Project of China (no. 2010CB912802 and 2010CB529401), and Project of Guangdong Science and Technology Agency (no. 2004B35001004).

 
dc.identifier.issn1048-891X
2012 Impact Factor: 1.941
2012 SCImago Journal Rankings: 0.762
 
dc.identifier.issue3
 
dc.identifier.pmid21436696
 
dc.identifier.scopuseid_2-s2.0-80051647936
 
dc.identifier.spage486
 
dc.identifier.urihttp://hdl.handle.net/10722/137271
 
dc.identifier.volume21
 
dc.languageeng
 
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at tp://www.ijgc.net/
 
dc.publisher.placeUnited States
 
dc.relation.ispartofInternational Journal of Gynecological Cancer
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdenocarcinoma, Mucinous - metabolism - pathology
 
dc.subject.meshCell Adhesion Molecules - metabolism
 
dc.subject.meshCystadenocarcinoma, Serous - metabolism - pathology
 
dc.subject.meshImmunoglobulins - metabolism
 
dc.subject.meshOvarian Neoplasms - metabolism - pathology
 
dc.subjectImmunohistochemistry
 
dc.subjectOvarian tumor
 
dc.subjectPrognosis
 
dc.subjectTSLC1
 
dc.titleLoss/down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yang, G</contributor.author>
<contributor.author>He, W</contributor.author>
<contributor.author>Cai, M</contributor.author>
<contributor.author>Luo, F</contributor.author>
<contributor.author>Kung, H</contributor.author>
<contributor.author>Guan, X</contributor.author>
<contributor.author>Zeng, Y</contributor.author>
<contributor.author>Xie, D</contributor.author>
<date.accessioned>2011-08-26T14:22:13Z</date.accessioned>
<date.available>2011-08-26T14:22:13Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>International Journal Of Gynecological Cancer, 2011, v. 21 n. 3, p. 486-493</identifier.citation>
<identifier.issn>1048-891X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137271</identifier.uri>
<description.abstract>Objectives: The tumor suppressor in lung cancer 1 (TSLC1) has been identified as a putative tumor suppressor gene in non-small cell lung cancer. Although loss of TSLC1 has been observed in a number of human malignancies, the expression levels of TSLC1 gene in ovarian cancer and its clinical or prognostic significance have not been investigated. Methods: Protein expression levels of TSLC1 was explored by semiquantitative immunohistochemical staining on archival formalin-fixed, paraffin-embedded pathological specimen consisting of 30 normal ovaries, 30 ovarian cystadenomas, 40 borderline ovarian tumors, and 160 invasive ovarian carcinomas. The TSLC1 immunohistochemical staining results were then correlated with various clinicopathologic parameters and patient prognosis using various statistical models. Results: Significantly decreased, or complete loss of, protein expression of the TSLC1 gene was observed in 59%ovarian carcinomas, 45% borderline tumors, and 7% cystadenomas, but in none of the normal ovaries (0%). In ovarian carcinomas, decreased TSLC1 expression was significantly correlated with lymph node metastasis (pN, P = 0.001), distant metastasis (pM, P = 0.028), and more advanced International Federation of Gynecology and Obstetrics stages (P = 0.008). By univariate survival analysis on the ovarian carcinoma cohorts, decreased TSLC1 protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P &lt; 0.001). By multivariate analysis, TSLC1 protein expression remained as a significant and independent prognostic factor for the prediction of patient survival (P = 0.003). Conclusions: Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma. Thus, TSLC1 may be used as an independent prognostic molecular marker for patients with ovarian carcinoma. Copyright &#169; 2011 by IGCS and ESGO.</description.abstract>
<language>eng</language>
<publisher>Lippincott Williams &amp; Wilkins. The Journal&apos;s web site is located at tp://www.ijgc.net/</publisher>
<relation.ispartof>International Journal of Gynecological Cancer</relation.ispartof>
<subject>Immunohistochemistry</subject>
<subject>Ovarian tumor</subject>
<subject>Prognosis</subject>
<subject>TSLC1</subject>
<subject.mesh>Adenocarcinoma, Mucinous - metabolism - pathology</subject.mesh>
<subject.mesh>Cell Adhesion Molecules - metabolism</subject.mesh>
<subject.mesh>Cystadenocarcinoma, Serous - metabolism - pathology</subject.mesh>
<subject.mesh>Immunoglobulins - metabolism</subject.mesh>
<subject.mesh>Ovarian Neoplasms - metabolism - pathology</subject.mesh>
<title>Loss/down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1097/IGC.0b013e31820fa168</identifier.doi>
<identifier.pmid>21436696</identifier.pmid>
<identifier.scopus>eid_2-s2.0-80051647936</identifier.scopus>
<identifier.hkuros>190875</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-80051647936&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>21</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>486</identifier.spage>
<identifier.epage>493</identifier.epage>
<identifier.isi>WOS:000288743700011</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. Sun Yat-Sen University